United Therapeutics
UTHR
545.00
+3.38
+0.62%
United Therapeutics
US · UTHR
#836 by market cap
Listed 1970
545.00
+3.38
+0.62%
Live - 5344 symbols - heartbeat 91s ago
· 2026-10-08 06:19
Pre-market
546.17
+0.21%
After-hours
545.00
0.00%
Overnight
546.00
+0.18%
- Market cap
- 23.38B
- P/E (TTM)i
- 19.53
- P/Bi
- 3.65
- EPSi
- 27.86
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on UTHR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.9 percentage points.
Institutional ownership
- Held by institutions
- 99.38% -0.88pp
- Institutions
- 1,058 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund66.96%
Hedge Fund20.37%
Public Company3.25%
Government Pension Fund3.01%
Private Company2.65%
Individual/Insider1.95%
Sovereign Wealth Fund1.67%
VC/PE Fund0.60%
Insurance Company0.33%
Top holders as of 2026-06-30
BlackRock
12.34% · 5.29M sh
Avoro Capital Advisors LLC
6.48% · 2.78M sh
Vanguard Capital Management, LLC
5.10% · 2.19M sh
Vanguard Portfolio Management, LLC
4.48% · 1.92M sh
State Street Global Advisors
4.43% · 1.90M sh
Renaissance Technologies Corp.
3.98% · 1.71M sh
Wellington Management Group
3.22% · 1.38M sh
Geode Capital Management, LLC
2.32% · 996.60K sh
Janus Henderson Group plc
1.94% · 831.13K sh
Norges Bank Investment Management
1.62% · 694.75K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 0 buys · 50 sells
| Name | Role | Stake |
|---|---|---|
| Martine Rothblatt | Chairperson & CEO | 1.56% |
| Paul Mahon | General Counsel | 0.11% |
| Thomas Thompson | Independent Director | 0.05% |
| Richard Giltner | Independent Director | 0.05% |
| Michael Benkowitz | President | 0.05% |
| James Edgemond | Chief Financial Officer | 0.04% |
| Raymond Kurzweil | Independent Director | 0.03% |
| Nilda Mesa | Independent Director | 0.01% |
| Judy Olian | Independent Director | 0.01% |
| Louis Sullivan | Independent Director & Member of the Scientific Advisory Board | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–574.23 |
| 2026-09-30 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–584.66 |
| 2026-09-30 | Paul Mahon | General Counsel | Derivative Exercise and Sale | -8,300 | $146.03–573.15 |
| 2026-09-28 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–486.77 |
| 2026-09-27 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–486.01 |
| 2026-09-24 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–478.95 |
| 2026-09-23 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–480.33 |
| 2026-09-22 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–500.05 |
| 2026-09-21 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–499.07 |
| 2026-09-20 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–496.62 |
| 2026-09-17 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–498.25 |
| 2026-09-16 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–501.60 |
| 2026-09-16 | Paul Mahon | General Counsel | Derivative Exercise and Sale | -8,300 | $146.03–501.58 |
| 2026-09-15 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–505.20 |
| 2026-09-14 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–504.57 |
| 2026-09-13 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–506.48 |
| 2026-09-13 | Nilda Mesa | Independent Director | Open Market Disposition | -98 | $505.98 |
| 2026-09-13 | Nilda Mesa | Independent Director | Derivative Exercise and Sale | -130 | $110.86–505.79 |
| 2026-09-10 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–508.21 |
| 2026-09-09 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–508.80 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:19:20 · For reference only, not investment advice and not tailored to your situation.